Optivo, an immunotherapy used to treat certain types of cancer, showed a positive result in gastric cancer clinical trials that involved Koreans. The study demonstrated a 47% reduction in the disease progression and death risk compared to conventional therapies.

According to industry sources on November 6th, Bristol Myers Squibb (BMS) and Ono Pharmaceutical have recently presented the subgroup analysis results from Phase 3 'ATTRACTION-4,' evaluating Optivo as a treatment for East Asian patients.

The clinical trial involved 724 patients with HER2-negative gastric cancer, including 291 Korean patients. The study evaluated Optivo in combination with platinum-based chemotherapy as a first-l